Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study-Reference-Cited by-同舟云学术

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

Published:2022-03-04 Issue:7 Volume:63 Page:1660-1668
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Garcia-Manero Guillermo¹^ORCID,Ribrag Vincent²,Zhang Yayan³,Farooqui Mohammed³,Marinello Patricia³,Smith B. Douglas⁴

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Hematology, Gustave Roussy, Villejuif, France

3. Department of Medical Oncology, Merck & Co., Inc, Kenilworth, NJ, USA

4. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Funder

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2034155

Reference21 articles.

1. Myelodysplastic Syndromes

2. Myelodysplastic syndromes: moving towards personalized management

3. Medical Conditions and Modifiable Risk Factors for Myelodysplastic Syndrome: A Systematic Review

4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): myelodysplatic syndromes (Version 3.2021). 2021. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-cell dysfunctions in myelodysplastic syndromes;Blood;2024-04-04

2. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape;Current Oncology;2024-04-03

3. Immune checkpoint blockade in hematological malignancies: current state and future potential;Frontiers in Oncology;2024-01-23

4. Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies;Clinical Lymphoma Myeloma and Leukemia;2024-01

5. Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress;Cancers;2023-10-19